EUCTR2012-001699-12-ES进行中（未招募）不适用
Prospective, open uncontrolled study to evaluate the safety of Depigoid with two pollen combinations ( Grasses/Olea and Grasses/ Parietaria) 2000 DPP/ml in patients with allergic rhinitis or rhinoconjunctivitis with or without seasonal asthma.
aboratorios LETI, S.L.0 个研究点开始时间: 2012年8月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Subject has dated and signed the informed consent.
- •-Men and women between 18 and 60 years of age (both inclusive).
- •-Individuals suffering symptoms of allergic rhinoconjunctivitis or rhinitis during at least the preceding year, with or without allergic seasonal asthma caused by a clinically relevant sensitization to pollens (grasses AND P. judaica or O. europaea). Asthmatic patients can be included in the trial only if seasonal asthma is controlled with a medium daily dose minor or equal to 800 µg/day of budesonide or an equivalent or minor or equal to 400 µg/day of budesonide or an equivalent plus a long-acting-?2 agonist.
- •- Asthmatic patients must be stable within 3 months prior to Visit 1 and on an stable inhaled steroid dose within 6 weeks prior to visit 1 and throughout the study. FEV1 must be ? 80% of predicted value.
- •-The IgE-mediated sensitization must be demonstrated by the following: medical history AND IgE specific CAP RAST ? 2 to the suspected relevant pollens (grass pollen AND Olea and/or Parietaria) AND a positive skin prick test to grass and Olea and/or Parietaria.
- •A skin prick test will be considered positive when it produces a wheal of at least 3 mm according to the largest diameter.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 54
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Any contraindication for treatment with allergen specific immunotherapy.
- •-Forced expiratory volume in 1 s (FEV1) or peak expiratory flow (PEF) value <80% of the predicted normal value.
- •-Clinically relevant allergy symptoms due to sensitization to perennial allergens (mites, molds, epithelia) or other seasonal pollen which might interfere with the safety of the IMP.
- •-Asthma requiring a dose > 800 µg/day of Budesonide or an equilent, without long-lasting beta-2 agonists or requiring a dose > of 400 µg/day of Budesonide or an equivalent plus a long-acting-?2 agonist to reach asthma control, according to the Global Initiative for Asthma (GINA 2010)
- •-Patients with non controlled bronchial asthma within 3 months prior to Visit 1.
- •-Patients with asthma who have been treated with systemic steroids within 3 months prior to V1.
- •-Patients with hospital admission due to asthma exacerbations within 1 year prior to V1.
- •-Acute or chronic inflammatory or infectious diseases of the airways.
- •-Chronic structural diseases of the respiratory system (for example, emphysema or bronchiectasis).
- •-Immune system diseases, both autoimmune diseases and immunodeficiency.
- •-Any disease involving a contraindication for the use of adrenaline (for example, hyperthyroidism).
- •-Serious uncontrolled diseases involving a risk for the subjects participating in this study, including the following for example: heart failure, serious or uncontrolled respiratory diseases, endocrine diseases, clinically relevant liver or kidney diseases or hematological diseases.
- •-Malignant disease with activity in the last 5 years.
- •-Excessive consumption of alcohol, drugs or medication.
- •-Serious psychiatric, psychological or neurological disorders.
- •-Systemic or topical treatment with beta-blocker drugs 1 week before visit 2.
- •-Treatment with substances interfering with the immune system 2 weeks before visit 2.
- •-Use of tricyclic, tetracyclic and IMAO antidepressants. It will not be allowed to wash up antidepressants to enter the study because of the risks of interrupting antidepressant treatment, so patients on antidepressants therapy cannot be included in the trial.
- •-Use of systemic corticosteroids 3 months before visit 1.
- •-Immunization with prophylactic (bacterial or viral) vaccines within 7 days before visit 1 (prophylactic vaccines are allowed during the administration of IMP period provided they are administered at least one week after IMP administration and the next IMP administration is administered at least 14 days later).
- •-Participation of the subject in another clinical trial 30 days before visit 2
- •-Subjects who are going to donate stem cells, blood, organs or bone marrow in the course of the study.
- •-Female subjects who are pregnant or nursing and women with a positive pregnancy test at visit 1 or 2.
- •-Women of childbearing potential not using highly effective methods of birth control. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner. Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.
- •-No written informed consent upon enrolment.
- •-Subjects who are unable to comply with the requirements of the study or who in the opinion of t
研究者
相似试验
招募中
不适用
A clinical trial to study the efficacy of daily versus twice weekly therapy with oral calcitriol for controlling secondary hyperparathyroidsim in pre-dialysis CKD patients.CTRI/2011/12/002263AIIMS50
进行中（未招募）
4 期
Study to evaluate the efficacy and safety of salmon protein hydrolyate in whey protein isolate powder to improve hemoglobin and serum ferritin in anaemic patientsCTRI/2014/02/004433Hofseth Biocare AS48
招募中
1 期
An open-label, uncontrolled study to evaluate the efficacy and safety of autologous bone marrow mesenchymal stem cells (LS-ABMSC1) in patients with decompensated liver cirrhosis (Phase I / II study)Decompensated liver cirrhosisJPRN-jRCT2063200014Takami Taro10
尚未招募
2 期
An open-label, uncontrolled study to evaluate the safety and immunogenicity of FPP003 in subjects with axial spondyloarthritis (phase IIa study)Axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis not meeting radiographicJPRN-jRCT2050230093Tsuji Shigeyoshi6
招募中
1 期
An open-label, uncontrolled study to evaluate the efficacy and safety of autologous bone marrow mesenchymal stem cells (LS-ABMSC1) in patients with decompensated liver cirrhosis (Phase I / II study)JPRN-UMIN000041461Yamaguchi University Graduate School of Medicine10